• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cristian Massacesi, M.D., Appointed to Replay Board of Directors

    5/25/23 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Cristian Massacesi, M.D., Appointed to Replay Board of Directors

    • Cristian Massacesi, M.D., Chief Medical Officer of AstraZeneca and Alexion and Oncology Chief Development Officer of AstraZeneca, to support Replay in advancing genomic medicine and cell therapy pipeline
    • Dr. Massacesi brings over 20 years of research and medicines development experience to the Replay Board

    San Diego, California and London, UK, May 25, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the appointment of Cristian Massacesi, M.D., as a member of its Board of Directors, with immediate effect.

    Dr. Massacesi is a leading expert in medical oncology, with over 20 years of research and drug development experience in the pharmaceutical industry. Dr. Massacesi is the Chief Medical Officer of AstraZeneca (NASDAQ:AZN) and Alexion, where he oversees patient safety and quality assurance activities for the entire company portfolio – from investigational drugs to established products. He is also the Oncology Chief Development Officer at AstraZeneca, where he leads the global development and operations of its late-stage Oncology portfolio of innovative medicines and immunotherapies, comprising more than 160 studies spanning multiple indications. His role and responsibilities at AstraZeneca continue unchanged.

    Prior to AstraZeneca, Dr. Massacesi held several other senior leadership roles. He was Vice President, and Medicine Team Leader Immuno-Oncology at Pfizer, where he led multiple development programs in lung cancer, head and neck cancer, and hematological malignancies, and supported the oncology business development and pipeline strategy.

    Dr. Massacesi was also Vice President, and Senior Global Clinical Program Head for the Immunotherapy Centre of Excellence at Novartis, and the Oncology Global Development and Global Medical Affairs Paris Site Head. Prior to that, as Global Clinical Program Head, he led the company's PI3K-inhibitors portfolio through clinical development, including registrational studies and submissions.

    Dr. Massacesi began his Academic career at Marche Polytechnic University in Italy, where he worked in the Department of Medical Oncology and Radiotherapy. He holds postgraduate degrees from the School of Oncology and School of Forensic Medicine at Marche Polytechnic University and received his medical oncology training at the Royal Marsden Hospital in London, UK, the Kaplan Comprehensive Cancer Center, NY, USA, and the European Institute of Oncology, Italy.

    Dr. Massacesi has authored over 50 peer-reviewed papers and 100 conference abstracts on a wide range of cancer topics and lectured on subjects that include immunotherapy clinical trials, breast cancer, and the clinical development of PI3K-inhibitors. Dr. Massacesi has authored multiple patents on cancer treatment combinations and regimens.

    Adrian Woolfson, Executive Chairman, President, and Co-founder of Replay, commented: "Cristian has an exceptional reputation within the life sciences community and his extensive experience and expertise in leading oncology clinical development programs is a significant addition to Replay's board. His breadth of industry knowledge, especially in the field of immuno-oncology, will be invaluable to Replay's continued growth, as we build out our first-in-class portfolio of TCR-NK cell therapies and HSV-based gene therapies to address some of the most significant challenges in cell therapy and genomic medicine. On behalf of the Board of Directors, I am delighted to welcome Cristian to the company and look forward to working with him as we continue to build an enduring enterprise with the potential to shape the future of the industry."

    Lachlan MacKinnon, CEO and Co-Founder of Replay, added, "Replay's genomic medicine toolkit encompasses a broad portfolio of disruptive platform technologies to write and deliver big DNA that we are advancing within our distinct hub-and-spoke business model. Our Board brings together unrivalled expertise across a wide range of specialties that support this, and Cristian's unique knowledge and skill set, especially within the immuno-oncology space, will be invaluable as we continue to drive the strategy forward."

    Kugan Sathiyanandarajah, Managing Director at KKR and Board Member at Replay, stated, "We are thrilled to have Cristian joining the Board. His extensive experience in oncology drug development within the pharmaceutical industry will be of immense value as Replay transitions into a clinical-stage company with the potential to significantly impact the healthcare sector."

    Commenting on his appointment, Cristian Massacesi said, "Replay has the potential to transform the future of cell therapy and genomic medicine in general through its unique portfolio of technology platforms and innovative approach to product development. I am excited to be joining as a board member and to be supporting such a strong and dynamic team. It's a pivotal moment in the company's development as it progresses its first-in-class, engineered TCR-NK cell therapies and HSV-based gene therapies into the clinic, and I'm pleased to be able to bring my knowledge and experience to help Replay's mission."

    Ends

    About Replay

    Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform – to address the challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential.

    The company's hub-and-spoke business model separates technology development within Replay from therapeutic development in a portfolio of product companies that leverage its technology platforms. For example, the Company recently incorporated a first-in-class engineered TCR-NK cell therapy product company using technology developed by Professor Katy Rezvani at the MD Anderson Cancer Center in Houston, Texas. Replay's synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay's four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. Replay is led by a distinguished team of academics, entrepreneurs, and industry experts.

    The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.

    Replay is headquartered in San Diego, California. For further information please visit www.replay.bio and follow us on LinkedIn and Twitter.

    Contacts:

    Replay

    Dr Adrian Woolfson/Lachlan MacKinnon

    [email protected]

    Consilium Strategic Communications – Media relations

    Amber Fennell/David Daley /Melissa Gardiner

    [email protected]



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

      Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

      6/24/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

      Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and AstraZeneca's DATROWAY in less than six months DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinic

      6/23/25 5:05:00 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer

      The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. DESTINY-Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. (GOG-F) and the European Network of Gynecological Oncological Trial (ENGOT). ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi S

      6/9/25 8:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/7/25 6:24:13 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/1/25 11:34:02 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by AstraZeneca PLC

      11-K - ASTRAZENECA PLC (0000901832) (Filer)

      6/26/25 3:00:03 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care